"Cardiotonic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE).
| Descriptor ID |
D002316
|
| MeSH Number(s) |
D27.505.954.411.222 D27.720.799.080
|
| Concept/Terms |
Cardiotonic Agents- Cardiotonic Agents
- Cardiac Stimulants
- Inotropic Agents, Positive Cardiac
- Cardiotonic Drugs
- Cardiotonics
- Myocardial Stimulants
- Cardioprotective Agents
|
Below are MeSH descriptors whose meaning is more general than "Cardiotonic Agents".
Below are MeSH descriptors whose meaning is more specific than "Cardiotonic Agents".
This graph shows the total number of publications written about "Cardiotonic Agents" by people in this website by year, and whether "Cardiotonic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 0 | 2 | 2 |
| 1999 | 1 | 0 | 1 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 3 | 4 |
| 2006 | 7 | 1 | 8 |
| 2007 | 2 | 2 | 4 |
| 2008 | 2 | 3 | 5 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 3 | 3 | 6 |
| 2012 | 2 | 2 | 4 |
| 2013 | 2 | 3 | 5 |
| 2014 | 5 | 4 | 9 |
| 2015 | 2 | 3 | 5 |
| 2016 | 1 | 1 | 2 |
| 2017 | 2 | 0 | 2 |
| 2018 | 3 | 1 | 4 |
| 2019 | 5 | 2 | 7 |
| 2020 | 1 | 2 | 3 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 2 | 2 |
| 2024 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cardiotonic Agents" by people in Profiles.
-
Comorbidities, pharmacologic interventions, and mechanical interventions associated with mortality in isolated diastolic left heart failure: lessons from a national database. Cardiol Young. 2025 Jan; 35(1):102-108.
-
Clinical Interventions and Hemodynamic Monitoring in the Setting of Left Ventricular Systolic Heart Failure in Children: Insights From a Physiologic Simulator. Am J Ther. 2024 Sep-Oct 01; 31(5):e531-e540.
-
Levosimendan for Diastolic Dysfunction? Cardiovasc Drugs Ther. 2024 Oct; 38(5):1053-1054.
-
Nonresponse to Heart?Failure?Therapy: An Important Trajectory. JACC Heart Fail. 2023 06; 11(6):729-732.
-
Milrinone therapeutic drug monitoring to reduce low cardiac output syndrome in pediatric patients. Can J Anaesth. 2023 05; 70(5):922-924.
-
Update on cardiogenic shock: from detection to team management. Curr Opin Cardiol. 2023 03 01; 38(2):108-115.
-
Long-Term Ambulatory Intravenous Milrinone Therapy in Advanced Heart Failure. Heart Lung Circ. 2022 Dec; 31(12):1630-1639.
-
Milrinone or dobutamine in patients with heart failure: evidence from meta-analysis. ESC Heart Fail. 2022 06; 9(3):2049-2050.
-
A Mistake Not to Be Repeated: What Can We Learn from the Underutilization of Statin Therapy for Efficient Dissemination of Cardioprotective Glucose Lowering Agents? Curr Cardiol Rep. 2022 06; 24(6):689-698.
-
Efficacy and safety of levosimendan and dobutamine in heart failure: A systematic review and meta-analysis. Cardiol J. 2021; 28(3):492-493.